Metabolic Effects of Medium-Chain Fatty Acids in Patients With Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Healthy Individuals

Key facts

Sponsor

University of Copenhagen

Principal Investigator

Andreas M Fritzen, Associate Professor

University of Copenhagen

Intervention

Medium-Chain Fatty Acid (MCFA)(other)

Enrollment

30 enrolled

Eligibility

18-80 years · All sexes

Timeline

2024 – 2027

Study locations (1)

• University of Copenhagen, Copenhagen, Denmark

Collaborators

Copenhagen Neuromuscular Center · Center of Inherited Metabolic Diseases, Copenhagen University Hospital Rigshospitalet · Section of Molecular Physiology, Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Denmark

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acyl-CoA dehydrogenase deficiency

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07097311
  Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
  Jerry Vockley, MD, PhD
• RECRUITINGPHASE2NCT06773026
  Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
  Jerry Vockley, MD, PhD

See all trials for Acyl-CoA dehydrogenase deficiency →